Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2008 Sep;23(9):1507-13.
doi: 10.1007/s11606-008-0655-4. Epub 2008 Jun 3.

Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis

Mary C Politi  1 , Mark D Schleinitz, Nananda F Col
Affiliations
Meta-Analysis

Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis

Mary C Politi et al. J Gen Intern Med. 2008 Sep.

Abstract

Background: Treatment decisions about menopause are predicated on a transient duration of vasomotor symptoms. However, evidence supporting a specific duration is weak.

Objective: To estimate the natural progression of vasomotor symptoms during the menopause transition by systematically compiling available evidence using meta-analytic techniques.

Data sources: We searched MEDLINE, hand searched secondary references in relevant studies, book chapters, and review papers, and contacted investigators about relevant published research.

Review methods: English language, population-based studies reporting vasomotor symptom prevalence among women in menopausal transition in time intervals based on years to or from final menstrual period were included. Two reviewers independently assessed eligibility and quality of studies and extracted data for vasomotor symptom prevalence.

Results: The analyses included 10 studies (2 longitudinal, 8 cross sectional) with 35,445 participants. The percentage of women experiencing symptoms increased sharply in the 2 years before final menstrual period, peaked 1 year after final menstrual period, and did not return to premenopausal levels until about 8 years after final menstrual period. Nearly 50% of all women reported vasomotor symptoms 4 years after final menstrual period, and 10% of all women reported symptoms as far as 12 years after final menstrual period. When data were examined according to symptom severity ('any' vs. 'bothersome'), bothersome symptoms peaked about 1 year earlier and declined more rapidly than symptoms of any severity level.

Conclusions: Our findings suggest a median symptom duration of about 4 years among symptomatic women. A longer symptom duration may affect treatment decisions and clinical guidelines. Further prospective, longitudinal studies of menopausal symptoms should be conducted to confirm these results.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flow diagram.
Figure 2
Figure 2
Vasomotor symptom prevalence by years to/from final menstrual period. Six studies [,–21] provided data for the main meta-analysis. One [2] was longitudinal, and the others were cross-sectional. The onset of menopause (Y0) coincides with the final menstrual period (FMP). One year after FMP corresponds to Y1, two years after, Y2, etc, whereas Y−1 represents 1 year before FMP.
Figure 3
Figure 3
Pooled estimates of proportion of vasomotor symptoms by years to/from final menstrual period. Six studies [,–21] provided data for the main meta-analysis. One [2] was longitudinal, and the others were cross-sectional.
Figure 4
Figure 4
Meta-analysis stratified by symptom severity. Six studies [,–21] provided data for the main meta-analysis. One [2] was longitudinal, and the others were cross-sectional. The fitted trendlines (Fig. 4) were created to represent the pattern of vasomotor symptom prevalence over time, using a third order polynomial function.
See this image and copyright information in PMC

Comment in

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/0378-5122(92)90003-M', 'is_inner': False, 'url': 'https://doi.org/10.1016/0378-5122(92)90003-m'}, {'type': 'PubMed', 'value': '1565019', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/1565019/'}]}
    2. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas. 1992;14(2):103–15. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1080/713605371', 'is_inner': False, 'url': 'https://doi.org/10.1080/713605371'}, {'type': 'PubMed', 'value': '12841881', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12841881/'}]}
    2. Guthrie J, Dennerstein L, Taffe J, Donnelly V. Health care-seeking for menopausal problems. Climacteric. 2003;6(2):112–7. - PubMed
    1. Lobo R (ed). Treatment of the postmenopausal woman: Basic and clinical aspects.: Academic Press; 2007.
    1. Medical Knowledge Self Assessment Program 14. 2007.
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1097/01.GME.0000108177.85442.71', 'is_inner': False, 'url': 'https://doi.org/10.1097/01.gme.0000108177.85442.71'}, {'type': 'PubMed', 'value': '14716179', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/14716179/'}]}
    2. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: Position statement of The North American Menopause Society. Menopause. 2004;11:11–33. - PubMed

Publication types